Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Aliaksandr Skrahin (Minsk, Belarus), Aliaksandr E. Skrahin, Helen E. Jenkins, Hennadz Hurevich, Varvara Solodovnokova, Yanina Isaikina, Dzmitri Klimuk, Zoya Rohava, Alena Skrahina. Potential role of autologous mesenchymal stromal cells in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur Respir J 2016; 48: Suppl. 60, 1919

Member's Comments

No comment yet.

Related content which might interest you: Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis (M/XDR-TB): An open-label phase 1 safety trial Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014 Adjuvant therapy with autologus mesenchymal stem cells in extensively drug-resistant pulmonary tuberculosis. A case study Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 The experience of additional treatment of MDR-TB patients using autologous mesenchymal stem cells Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Immunophenotypic characterisation of peripheral blood mononuclear cells in patients with MDR pulmonary tuberculosis Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers Year: 2016 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis Source: Annual Congress 2009 - Priorities in tuberculosis research Year: 2009 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis Source: Eur Respir J 2009; 34: 180-183 Year: 2009 Risk factors for treatment failure in multidrug-resistant and extensively drug-resistant tuberculosis in Estonia Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 Management and treatment of multidrug-resistant tuberculosis Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management Year: 2019 A multicentric cohort analysis of culture conversion and reversion in multidrug resistant tuberculosis (MDRTB) patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Short term effects of dendritic cell based immunotherapy in multiple and extensively drug resistant pulmonary tuberculosis in Belarus Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Side effects of chemical preparations in patients with drug-resistant pulmonary tuberculosis Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015